About Half of Lung Cancer Patients with Medicare Don’t Receive the Appropriate Imaging Before Treatment

 

The leading cause of cancer-related death in the United States is lung cancer. According to a study published in the Journal of Nuclear Medicine in January, roughly half of Medicare patients with Non-Small Cell Lung Cancer (NSCLC) do not receive the appropriate imaging before radiation treatment. 

Research has shown that up to 72 percent of patients with lung cancer who receive NSCLC with FDG PET/CT imaging have seen various treatment changes. Compared to patients who underwent CT imaging alone, patients with FDG PET/CT imaging had substantially improved cancer-specific survival rates. 

As a result, National Comprehensive Cancer Network (NCCN) guidelines have changed to suggest all recurrent NSCLC patients receive FDG PET/CT to evaluate for metastatic disease. 

The study conducted by researchers examined over 5,000 patients with NSCLC requiring radiation therapy. Those who received only CT imaging were in one group, and those who received additional FDG PET/CT were in another. Scientists investigated the overall and cancer-specific survival rates of both groups. 

When comparing survival rates after three years, those who received only CT imaging had substantially lower overall and cancer-specific survival rates compared to patients who underwent FDG PET/CT imaging. 

In total, 56.3 percent of patients experienced FDG PET/CT before radiation therapy, and 43.6 percent had CT imaging alone. 

Rustain Morgan, MD, MS, a nuclear radiologist at the University of Colorado in Aurora, Colorado, said, “This research shows a clear lack of adherence to guidelines and raises important questions as to why. We believe these findings are the tip of the iceberg for guideline nonadherence. More work needs to be done in order to better understand the scope of the issue, with further work focused on interventions which ensure guideline adherence.”

_____________________________________

RadParts, a TTG Imaging Solutions Company, is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerators and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost components and support for linear accelerators and radiation equipment. Contact RadParts at  877-704-3838 to learn more.

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/ 

Novel 4D Printing Emerges for Breast Cancer Treatment

Breast cancer is the second most common cancer worldwide, affecting approximately 7.8 million women in the past seven years. Current 3D breast cancer treatment focuses on treatment, tissue regeneration, and physical recovery. From prosthetics to drug-loaded implants, challenges persist. With a novel 4D technology, complexity and customization combine to improve breast cancer management. 

Generally, 3D treatments are well-established due to many advantages, such as rapid prototyping, ease of accessibility, structural control, and cost-effectiveness. It also requires low energy, so from an environmental perspective, 3D treatments are eco-friendly, reduce waste production, and do not involve chemicals. There are some hurdles when it comes to 3D treatments, however. Some of these include build size, post-processing, and lack of regulation. 

When it comes to revolutionizing the standard treatment for breast cancer, 3D printing has shown a significant impact when it comes to diagnosis, treatment, and aesthetic outcomes. 

To help surgeons plan and make decisions, breast and tumor prototypes are used for diagnostic tasks, surgery training, preoperative planning, treatment optimization, and drug screening. These prosthetic models mimic patient anatomy. The 3D models, from a practical perspective, were created to localize tumors and provide physical models for resection guidance. 

With 4D treatments, the advantages and disadvantages of 3D technology are present, but 4D can offer a higher level of complexity and customization features. Combined with programmed functionalities, the dynamic abilities of 4D treatments are advantageous for breast cancer treatment. 

Some challenges of 4D treatment include material availability, technical aspects, and the design process. New materials and improved biocompatibility should be the primary focus when it comes to printability. 

RadParts, a TTG Imaging Solutions Company is the world’s largest independent distributor of OEM replacement parts. We specialize in low-cost parts for repairing linear accelerator and radiation equipment. Our mission is to provide high-quality, user-friendly, low-cost parts and support for linear accelerators and radiation equipment. Contact RadParts at 877-704-3838 to learn more.

 

Written by the digital marketing team at Creative Programs & Systems: https://www.cpsmi.com/